-
-
-
-
-
-
-
Aligos Therapeutics Inc. (ALGS) Misses Q1 EPS by 221c
-
-
-
-
-
-
-
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
-
-
-
-
-
-
-
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
-
-
-
-
-
-
-
Aligos begins phase 2 trial for hepatitis B treatment ALG-000184
-
-
-
-
-
-
-
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
-
-
-
-
-
-
-
Aligos Therapeutics Inc. (ALGS) Misses Q4 EPS by 1308c
-
-
-
-
-
-
-
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
-
1,211,668 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

